222 related articles for article (PubMed ID: 24845630)
21. Strategies and challenges for the next generation of therapeutic antibodies.
Beck A; Wurch T; Bailly C; Corvaia N
Nat Rev Immunol; 2010 May; 10(5):345-52. PubMed ID: 20414207
[TBL] [Abstract][Full Text] [Related]
22. Antibody fragments for controlled delivery of therapeutic agents.
Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
[No Abstract] [Full Text] [Related]
23. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
24. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
Weidle UH; Tiefenthaler G; Georges G
Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
[TBL] [Abstract][Full Text] [Related]
25. Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S; Sun Y; Liang X; Gu X; Ning J; Xu Y; Chen S; Pan L
Signal Transduct Target Ther; 2022 Feb; 7(1):39. PubMed ID: 35132063
[TBL] [Abstract][Full Text] [Related]
26. Emerging antibody-based therapies for the treatment of acute myeloid leukemia.
Angenendt L; Mikesch JH; Schliemann C
Cancer Treat Rev; 2022 Jul; 108():102409. PubMed ID: 35605472
[TBL] [Abstract][Full Text] [Related]
27. Advances in bispecific biotherapeutics for the treatment of cancer.
May C; Sapra P; Gerber HP
Biochem Pharmacol; 2012 Nov; 84(9):1105-12. PubMed ID: 22858161
[TBL] [Abstract][Full Text] [Related]
28. Bispecific antibody conjugates in therapeutics.
Cao Y; Lam L
Adv Drug Deliv Rev; 2003 Feb; 55(2):171-97. PubMed ID: 12564976
[TBL] [Abstract][Full Text] [Related]
29. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.
Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J
PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587
[TBL] [Abstract][Full Text] [Related]
30. Bispecific anti-mPDGFRβ x cotinine scFv-C
Kim S; Kim H; Jo DH; Kim JH; Kim SR; Kang D; Hwang D; Chung J
Methods; 2019 Feb; 154():125-135. PubMed ID: 30292795
[TBL] [Abstract][Full Text] [Related]
31. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.
Dengl S; Sustmann C; Brinkmann U
Immunol Rev; 2016 Mar; 270(1):165-77. PubMed ID: 26864111
[TBL] [Abstract][Full Text] [Related]
32. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties.
Rossi EA; Chang CH; Cardillo TM; Goldenberg DM
Bioconjug Chem; 2013 Jan; 24(1):63-71. PubMed ID: 23116517
[TBL] [Abstract][Full Text] [Related]
33. Biparatopic antibodies: therapeutic applications and prospects.
Niquille DL; Fitzgerald KM; Gera N
MAbs; 2024; 16(1):2310890. PubMed ID: 38439551
[TBL] [Abstract][Full Text] [Related]
34. [Bispecific antibodies, novel therapeutic candidates harnessing the immune system].
Chames P; Wurch T
Med Sci (Paris); 2019 Dec; 35(12):1072-1082. PubMed ID: 31903920
[TBL] [Abstract][Full Text] [Related]
35. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
36. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
Derby L; Czuczman MS
Future Oncol; 2011 Aug; 7(8):963-79. PubMed ID: 21823892
[TBL] [Abstract][Full Text] [Related]
37. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
Fazekas-Singer J; Singer J; Jensen-Jarolim E
Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
[TBL] [Abstract][Full Text] [Related]
38. Considerations for the Design of Antibody-Based Therapeutics.
Goulet DR; Atkins WM
J Pharm Sci; 2020 Jan; 109(1):74-103. PubMed ID: 31173761
[TBL] [Abstract][Full Text] [Related]
39. Bispecifics and antibody-drug conjugates: A positive synergy.
Maruani A
Drug Discov Today Technol; 2018 Dec; 30():55-61. PubMed ID: 30553521
[TBL] [Abstract][Full Text] [Related]
40. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model.
Patel A; DiGiandomenico A; Keller AE; Smith TRF; Park DH; Ramos S; Schultheis K; Elliott STC; Mendoza J; Broderick KE; Wise MC; Yan J; Jiang J; Flingai S; Khan AS; Muthumani K; Humeau L; Cheng LI; Wachter-Rosati L; Stover CK; Sardesai NY; Weiner DB
Nat Commun; 2017 Sep; 8(1):637. PubMed ID: 28935938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
